| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation | 44,279 |
| Realized loss on investments | 0 |
| Net income (loss) | 13,993 |
| Non-cash interest expense on credit facility | 48,774 |
| (accretion) amortization of note premiums/discounts | 4,545 |
| Prepaid expenses and other assets | 22,342 |
| Other | -3,128 |
| Operating lease, net | -3,417 |
| Deferred revenue | 22,979 |
| Accrued expenses | 7,956 |
| Accounts receivable | 9,841 |
| Accounts payable | 21,662 |
| Depreciation and amortization | 17,542 |
| Non-cash interest expense on liability related to the sale of future royalties | 18,893 |
| Net cash provided by (used in) operating activities | 159,061 |
| Proceeds from sales and maturities of investments | 587,880 |
| Purchases of property and equipment | 15,177 |
| Purchases of investments | 774,616 |
| Net cash used in investing activities | -201,913 |
| Repayments of credit facility | 201,625 |
| Proceeds from the exercises of stock options | 3,476 |
| Proceeds from visirna credit agreement | 7,098 |
| Proceeds from the issuance of warrants | 25,000 |
| Proceeds from the issuance of common stock, net of offering costs | 241,388 |
| Payments of debt issuance costs | 5,000 |
| Proceeds from the sales of future royalties | 0 |
| Net cash provided by financing activities | 70,337 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 27,485 |
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)